<DOC>
	<DOCNO>NCT01371565</DOCNO>
	<brief_summary>This compassionate use study . In addition provide compassionate use access mifepristone , objective study evaluate safety utility mifepristone treatment sign symptoms endogenous Cushing 's syndrome give compassionate use basis . The study enroll subject whose physician determine medical treatment need control symptoms sign hypercortisolemia .</brief_summary>
	<brief_title>Compassionate Use CORLUXÂ® ( Mifepristone ) Treatment Signs Symptoms Endogenous Cushing 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>1 . Have confirm diagnosis endogenous hypercortisolemia cause ACTH dependent ACTH independent etiology include : Cushing 's Disease ( one may apply ) recur primary pituitary surgery persist despite pituitary surgery ( fail pituitary surgery ) treat radiation therapy pituitary treatable surgery exist subject candidate refuse surgery Ectopic ACTH Ectopic CRF secretion Adrenal adenoma Adrenal carcinoma Adrenal autonomy 2 . Have document biochemical evidence endogenous hypercortisolemia include elevated urinary free cortisol . 3 . Require medical treatment hypercortisolemia . Individuals eligible enrol study : Have de novo Cushing 's disease surgical candidate pituitary surgery . Have acute unstable medical problem , could aggravate mifepristone treatment . Taking medication within 14 day baseline visit ( Day 1 ) ) large first pas metabolism largely mediate CYP3A4 narrow therapeutic margin and/or b ) strong CYP3A4 inhibitor . Female patient reproductive potential , pregnant unable unwilling use medically acceptable , nonhormonal method contraception study . Have receive investigational treatment ( drug , biological agent device ) within 30 day Screening Have history allergic reaction intolerance CORLUX ( mifepristone ) Have nonendogenous source hypercortisolemia factious hypercortisolemia ( exogenous source glucocorticoid , iatrogenic Cushing 's syndrome ) , factious therapeutic use ACTH Have PseudoCushing 's syndrome . Postmenopausal woman intact uterus experience unexplained vaginal bleeding within 12 month Screening exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Cushing 's Disease</keyword>
	<keyword>Cushing 's Syndrome</keyword>
	<keyword>Cushings</keyword>
	<keyword>Pituitary</keyword>
	<keyword>Ectopic ACTH secretion</keyword>
</DOC>